DRTS Stock Overview
A clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alpha Tau Medical Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.38 |
| 52 Week High | US$3.90 |
| 52 Week Low | US$1.75 |
| Beta | 0.78 |
| 11 Month Change | 8.95% |
| 3 Month Change | 9.95% |
| 1 Year Change | -27.59% |
| 33 Year Change | -75.94% |
| 5 Year Change | n/a |
| Change since IPO | -76.49% |
Recent News & Updates
Recent updates
Alpha Tau Medical (NASDAQ:DRTS) Has Debt But No Earnings; Should You Worry?
May 25
Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans
Nov 08Alpha Tau director gives up board seat to take up chief commercial officer role
Sep 02Alpha Tau Medical GAAP EPS of -$0.03
Aug 25Alpha Tau: Treating Cancer With Precision Alpha Radiation
Apr 12Shareholder Returns
| DRTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.5% | -0.3% | 1.6% |
| 1Y | -27.6% | 20.6% | 30.5% |
Return vs Industry: DRTS underperformed the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: DRTS underperformed the US Market which returned 30.5% over the past year.
Price Volatility
| DRTS volatility | |
|---|---|
| DRTS Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DRTS has not had significant price volatility in the past 3 months.
Volatility Over Time: DRTS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 121 | Uzi Sofer | www.alphatau.com |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. Fundamentals Summary
| DRTS fundamental statistics | |
|---|---|
| Market cap | US$171.31m |
| Earnings (TTM) | -US$27.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs DRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.63m |
| Earnings | -US$27.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.3% |
How did DRTS perform over the long term?
See historical performance and comparison